Day: April 24, 2024

BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023. Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023. Net income attributable to Amedisys, Inc. per diluted share of $0.44 compared to $0.77 in 2023.Adjusted Quarterly Results*Adjusted EBITDA of $59.9 million compared to $57.8 million in 2023. Adjusted...

First Quarter 2024Net Earnings of $48.6 million, or $0.35 per share Return on Average Assets of 1.21% Return on Average Tangible Common Equity of 15.13% Net Interest Margin of 3.10%ONTARIO, CA, April 24, 2024 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ:CVBF) and its subsidiary, Citizens Business Bank (the “Company”), announced earnings for the quarter ended March 31, 2024. CVB Financial Corp. reported net income of $48.6 million for the quarter ended March 31, 2024, compared with $48.5 million for the fourth quarter of 2023 and $59.3 million for the first quarter of 2023. Diluted earnings per share were $0.35 for the first quarter, compared to $0.35 for the prior quarter and $0.42 for the same period last year. Net income of $48.6 million for the first quarter of 2024 produced an annualized return on average equity (“ROAE”)...

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung study Multiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and data from MD Anderson program €75.3 million in cash and cash equivalents as of December 31, 2023 with cash runway into Q3 2025 including the $20 million first development milestone due from Janssen 2023 Universal Registration Document filed with the French financial market authority and the 2023 Annual Report on Form 20-F filed with...

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) today reported results for the first quarter of 2024. “With backlog of $6.3 billion, a strong bid pipeline, and recurring revenue programs continuing to see robust demand, Aecon is focused on achieving improved profitability and margin predictability, and believes it is positioned to achieve further revenue growth over the next few years,” said Jean-Louis Servranckx, President and Chief Executive Officer, Aecon Group Inc. “Moving forward, Aecon will continue to pursue and deliver the majority of its work in established markets and under more collaborative project delivery models, while embracing new opportunities to grow in areas linked to the energy transition and in select U.S. and international markets.” HIGHLIGHTSAll quarterly...

JACKSONVILLE, Fla., April 24, 2024 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ: LSTR) (“Landstar” or the “Company”) today reported basic and diluted earnings per share (“EPS”) of $1.32 in the 2024 first quarter on revenue of $1.171 billion. Landstar also announced today that its Board of Directors declared a quarterly dividend of $0.33 per share payable on May 24, 2024, to stockholders of record as of the close of business on May 8, 2024. “It’s been a privilege to join Landstar and work alongside our customers, independent agents, BCOs, employees and the Board. The Landstar team performed admirably in a challenging freight environment as both the number of loads hauled via truck and revenue per load on loads hauled via truck exceeded the high-end of the Company’s guidance issued in our 2023 fourth quarter earnings release,”...